Alunbrig

Active Ingredient(s): Brigatinib
FDA Approved: * April 28, 2017
Pharm Company: * ARIAD
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Alunbrig Overview

Brigatinib (INN;[1] marketed as Alunbrig) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc.[2] Brigatinib acts as both a anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) inhibitor. Brigatinib could overcome resistance to osimertinib conferred by the EGFR C797S mutation if it is combined with an anti-EGFR antibody such as cetuximab or panitumumab.[3] Contents...

Read more Alunbrig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Brigatinib

Recent Alunbrig Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Brigatinib

Tablet: 180mg, 30mg, 90mg

Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Alunbrig: (5 results)

Sorted by National Drug Code

63020-090 Alunbrig 90 mg Oral Tablet, Film Coated by Millennium Pharmaceuticals, Inc.
63020-113 Alunbrig 30 mg Oral Tablet, Film Coated by Millennium Pharmaceuticals, Inc.
63020-180 Alunbrig 180 mg Oral Tablet, Film Coated by Millennium Pharmaceuticals, Inc.
63020-198 Alunbrig Kit by Millennium Pharmaceuticals, Inc.
76189-113 Alunbrig 30 mg Oral Tablet, Coated by Ariad Pharmaceuticals Inc.

Other drugs which contain Brigatinib or a similar ingredient: (1 result)

BRIGATINIB